◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

Medicenna Therapeutics Corp.

Financial Statements (IFRS) · Amounts in CAD
5 10 All
Income Statement
Balance Sheet
Cash Flow
Line Item Q4 2025Dec 31, 2025 Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024
Total Revenue 0.00 0.00 0.00 0.00 0.00
Operating Revenue 0.00 0.00 0.00 0.00 0.00
Selling General And Administration 1.5M 1.3M 1.3M 1.2M 1.5M
General And Administrative Expense 1.5M 1.3M 1.3M 1.2M 1.5M
Research And Development 4.1M 4.1M 4.2M 4.5M 3.6M
Depreciation And Amortization In Income Statement 19,000 19,000 19,000 19,000 21,000
Operating Expense 5.6M 5.5M 5.5M 5.7M 5.1M
Operating Income -5.6M -5.5M -5.5M -5.7M -5.1M
EBIT -5.6M -5.5M -5.5M -5.7M -5.1M
Interest Income 114,000 158,000 204,000 264,000 378,000
Interest Income Non Operating 114,000 158,000 204,000 264,000 378,000
Net Interest Income 114,000 158,000 204,000 264,000 378,000
Other Income Expense 1.1M 429,000 377,000 6.6M -449,000
Gain On Sale Of Security 1.1M 429,000 377,000 6.6M -449,000
Pretax Income -4.4M -4.9M -4.9M 1.2M -5.2M
Tax Effect Of Unusual Items 0.00 0.00 0.00 996,300 0.00
Net Income From Continuing And Discontinued Operation -4.4M -4.9M -4.9M 1.2M -5.2M
Net Income From Continuing Operation Net Minority Interest -4.4M -4.9M -4.9M 1.2M -5.2M
Net Income Including Noncontrolling Interests -4.4M -4.9M -4.9M 1.2M -5.2M
Net Income Common Stockholders -4.4M -4.9M -4.9M 1.2M -5.2M
Net Income -4.4M -4.9M -4.9M 1.2M -5.2M
EBITDA -5.6M -5.4M -5.5M -5.7M -5.1M
Normalized EBITDA -6.7M -5.9M -5.9M -12.3M -4.7M
Reconciled Depreciation 16,000 23,000 19,000 19,000 18,000
Basic EPS -0.05 -0.06 -0.06 -- -0.07
Diluted EPS -0.05 -0.06 -0.06 -- -0.07
Basic Average Shares 83.4M 83.4M 82.5M -- 78.0M
Diluted Average Shares 83.4M 83.4M 82.5M -- 78.0M
Total Unusual Items 1.1M 429,000 377,000 6.6M -449,000
Total Unusual Items Excluding Goodwill 1.1M 429,000 377,000 6.6M -449,000
Tax Rate For Calcs 0.00 0.00 0.00 0.15 0.00
Normalized Income -5.5M -5.3M -5.3M -4.5M -4.7M
Depreciation Amortization Depletion Income Statement 19,000 19,000 19,000 19,000 21,000
Depreciation Income Statement 19,000 19,000 19,000 19,000 21,000
Diluted NI Availto Com Stockholders -4.4M -4.9M -4.9M 1.2M -5.2M
Net Income Continuous Operations -4.4M -4.9M -4.9M 1.2M -5.2M
Net Non Operating Interest Income Expense 114,000 158,000 204,000 264,000 378,000
Other Gand A 904,000 772,000 730,000 662,000 687,000
Salaries And Wages 620,000 572,000 553,000 544,000 820,000
Total Expenses 5.6M 5.5M 5.5M 5.7M 5.1M
Line Item Q4 2025Dec 31, 2025 Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024
Cash And Cash Equivalents 10.6M 15.7M 20.5M 24.8M 30.0M
Cash Cash Equivalents And Short Term Investments 10.6M 15.7M 20.5M 24.8M 30.0M
Cash Equivalents 8.9M 8.8M 14.0M 23.6M 27.5M
Cash Financial 1.8M 6.9M 6.5M 1.3M 2.5M
Receivables 1.5M 1.3M 1.2M 2.7M 1.4M
Prepaid Assets 835,000 861,000 947,000 639,000 588,000
Other Current Assets -- 2,000 -- -- --
Current Assets 12.9M 17.9M 22.6M 28.2M 32.0M
Gross PPE 103,000 120,000 142,000 159,000 175,000
Net PPE 103,000 120,000 142,000 159,000 175,000
Goodwill And Other Intangible Assets 48,000 49,000 50,000 52,000 53,000
Total Non Current Assets 151,000 169,000 192,000 211,000 228,000
Total Assets 13.1M 18.0M 22.8M 28.4M 32.2M
Current Debt And Capital Lease Obligation 65,000 62,000 58,000 49,000 40,000
Accounts Payable 4.3M 3.6M 3.2M 2.7M 1.9M
Payables 4.3M 3.6M 3.2M 2.7M 1.9M
Payables And Accrued Expenses 4.8M 4.4M 4.5M 4.4M 3.1M
Current Accrued Expenses 506,000 751,000 1.3M 1.7M 1.3M
Current Liabilities 4.8M 4.5M 4.6M 4.4M 3.2M
Long Term Debt And Capital Lease Obligation 70,000 87,000 104,000 119,000 134,000
Long Term Capital Lease Obligation 70,000 87,000 104,000 119,000 134,000
Total Non Current Liabilities Net Minority Interest 2.0M 3.3M 3.6M 4.9M 11.6M
Total Liabilities Net Minority Interest 6.9M 7.8M 8.1M 9.3M 14.8M
Common Stock 126.3M 126.2M 126.2M 116.3M 116.3M
Capital Stock 126.3M 126.2M 126.2M 116.3M 116.3M
Additional Paid In Capital 12.3M 12.0M 11.6M 11.2M 10.7M
Retained Earnings -132.4M -128.1M -123.2M -118.3M -119.4M
Gains Losses Not Affecting Retained Earnings 54,000 51,000 35,000 3,000 42,000
Other Equity Adjustments 54,000 51,000 35,000 3,000 42,000
Common Stock Equity 6.2M 10.2M 14.6M 19.1M 17.5M
Stockholders Equity 6.2M 10.2M 14.6M 19.1M 17.5M
Total Equity Gross Minority Interest 6.2M 10.2M 14.6M 19.1M 17.5M
Total Capitalization 6.2M 10.2M 14.6M 19.1M 17.5M
Net Tangible Assets 6.2M 10.2M 14.6M 19.0M 17.4M
Tangible Book Value 6.2M 10.2M 14.6M 19.0M 17.4M
Working Capital 8.1M 13.4M 18.0M 23.7M 28.8M
Invested Capital 6.2M 10.2M 14.6M 19.1M 17.5M
Total Debt 135,000 149,000 162,000 168,000 174,000
Share Issued 83.4M 83.4M 83.4M 78.2M 78.2M
Ordinary Shares Number 83.4M 83.4M 83.4M 78.2M 78.2M
Buildings And Improvements 101,000 115,000 128,000 141,000 154,000
Capital Lease Obligations 135,000 149,000 162,000 168,000 174,000
Current Capital Lease Obligation 65,000 62,000 58,000 49,000 40,000
Derivative Product Liabilities 2.0M 3.3M 3.5M 4.7M 11.5M
Other Equity Interest -- -- -- 9.8M 9.8M
Other Properties 2,000 5,000 14,000 18,000 21,000
Properties 0.00 0.00 0.00 0.00 0.00
Taxes Receivable 1.5M 1.3M 1.2M 2.7M 1.4M
Line Item Q4 2025Dec 31, 2025 Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024
Operating Cash Flow -5.0M -4.9M -3.5M -5.0M -3.6M
Cash Flow From Continuing Operating Activities -5.0M -4.9M -3.5M -5.0M -3.6M
Depreciation And Amortization 16,000 23,000 19,000 19,000 18,000
Depreciation Amortization Depletion 16,000 23,000 19,000 19,000 18,000
Stock Based Compensation 331,000 468,000 390,000 496,000 629,000
Change In Working Capital 185,000 -122,000 1.3M 963,000 540,000
Change In Receivables -176,000 -5,000 1.2M -289,000 240,000
Change In Payables And Accrued Expense 361,000 -117,000 128,000 1.3M 300,000
Other Non Cash Items 5,000 6,000 7,000 -1.0M 0.00
Capital Expenditure -- -- -- -- --
Purchase Of PPE -- 0.00 0.00 0.00 0.00
Net PPE Purchase And Sale 2,000 0.00 0.00 0.00 0.00
Investing Cash Flow 2,000 0.00 0.00 0.00 0.00
Cash Flow From Continuing Investing Activities 2,000 0.00 0.00 0.00 0.00
Repayment Of Debt -19,000 -19,000 -13,000 -- 0.00
Net Issuance Payments Of Debt -19,000 -19,000 -13,000 -- 0.00
Issuance Of Capital Stock 0.00 0.00 0.00 0.00 0.00
Net Common Stock Issuance 0.00 0.00 0.00 0.00 0.00
Financing Cash Flow -19,000 -19,000 39,000 -19,000 1.9M
Cash Flow From Continuing Financing Activities -19,000 -19,000 39,000 -19,000 1.9M
Effect Of Exchange Rate Changes -152,000 245,000 -871,000 -144,000 1.2M
Changes In Cash -5.0M -5.0M -3.5M -5.0M -1.6M
Beginning Cash Position 15.7M 20.5M 24.8M 30.0M 30.4M
End Cash Position 10.6M 15.7M 20.5M 24.8M 30.0M
Free Cash Flow -5.0M -4.9M -3.5M -5.0M -3.6M
Common Stock Issuance 0.00 0.00 0.00 0.00 0.00
Depreciation 16,000 23,000 19,000 19,000 18,000
Gain Loss On Investment Securities -1.3M -200,000 -1.3M -6.7M 1.6M
Long Term Debt Payments -19,000 -19,000 -13,000 -- 0.00
Net Foreign Currency Exchange Gain Loss 155,000 -229,000 903,000 105,000 -1.2M
Net Income From Continuing Operations -4.4M -4.9M -4.9M 1.2M -5.2M
Net Long Term Debt Issuance -19,000 -19,000 -13,000 -- 0.00
Operating Gains Losses -1.1M -429,000 -377,000 -6.6M 449,000
Proceeds From Stock Option Exercised 0.00 0.00 52,000 0.00 1.9M
NEWS
Loading news...
TRENDING
Loading...